Argenx Shares Down After Vyvgart Study Misses Primary Endpoint
By Dean Seal
Shares of Argenx dropped after the company said a study of its treatment for primary immune thrombocytopenia didn't meet its primary or secondary endpoints.
The stock fell 10% to $445 in premarket trading. Shares had gained 31% year-to-date when the market closed Monday.
The immunology company said early Tuesday morning that its study evaluating Vyvgart Hytrulo didn't meet the primary endpoint of a sustained platelet count response in patients with chronic primary immune thrombocytopenia, an autoimmune disorder.
"This is not the outcome we had hoped for patients," Chief Medical Officer Luc Truyen said.
Write to Dean Seal at dean.seal@wsj.com
(END) Dow Jones Newswires
November 28, 2023 06:48 ET (11:48 GMT)
Copyright (c) 2023 Dow Jones & Company, Inc.-
September Jobs Report Forecasts Show Moderate Hiring Gains
-
Port Strike a Headache for Shippers but a Potential Tailwind for Certain US Transport Stocks
-
13 Charts on Q3′s Roller-Coaster Rally for Stocks and Bonds
-
5 Stocks to Buy Instead of Overpriced US Equities
-
Q4 Stock Market Outlook: Where We See Opportunities for Investors
-
Markets Brief: Non-Farm Payrolls in the Spotlight Again
-
6 Top-Performing Large-Growth Funds
-
What’s the Difference Between the CPI and PCE Indexes?
-
This Cheap Stock Is Still a Buy Even After 50% Rally
-
10 Top-Performing Dividend Stocks of Q3 2024
-
33 Undervalued Stocks
-
Communication Services: Cable’s Broadband Dominance Isn’t as Strong as It Once Was
-
Technology: Strength Continues, With Software Presenting the Best Buying Opportunities
-
Best- and Worst-Performing Stocks of Q3 2024
-
Top Stocks to Own From the Best Fund Managers
-
2 Cheap Stocks Top Managers Have Been Buying